By Sabela Ojea
Shares of Anixa Biosciences climbed 14% to $4.47 in after-hours trading after the company presented positive results regarding its Phase 1 clinical trial of its breast cancer vaccine.
The biotechnology company said Wednesday its data exceeded management expectations.
“This vaccine is designed to direct the immune system to destroy triple negative breast cancer cells through a mechanism that has never previously been utilized for cancer vaccine development,” Chairman and Chief Executive Amit Kumar said.
Write to Sabela Ojea at [email protected]
Read the full article here